Healthtech MVPs die in two common ways: they never reach a real workflow because compliance fear freezes the roadmap, or they ship fast and discover too late that the architecture cannot survive BAA, audit, or clinical scrutiny. Both are avoidable if you treat compliance as a product constraint from week one — not a legal stamp at the end. This is not legal advice. It is a builder’s field guide from shipping software that touches clinical operations, patient communication, and regulated data without pretending a weekend hack is a medical device.
Separate “care delivery” from “care adjacent” early
Be precise about what the MVP does. Scheduling, education, and operational dashboards that never store protected health information are a different risk class from charting, diagnosis support, prescribing, or remote patient monitoring. If your pitch deck says “AI clinical decision support” but your first milestone is a waiting-room queue, say so out loud. Ambiguous scope is how founders accidentally build a regulated product with consumer-app habits. Write a one-page data map: what data you collect, why, where it lives, who can see it, how long you keep it, and which vendors touch it. That page becomes the spine for security questionnaires and architecture reviews.
Design for least privilege and boring infrastructure
Prefer architectures that make the safe path the default: strong tenant isolation, encryption in transit and at rest, short-lived credentials, audit logs on access to sensitive records, and environment separation that keeps production PHI out of staging screenshots. Avoid “shared demo databases” that mix customer data. Avoid pasting patient text into consumer LLM chats to “see if it works.” If you need AI, decide whether the model ever sees identifiers. Often the right MVP redacts, tokenizes, or keeps inference inside a VPC / BAA-covered stack. Speed that depends on pasting real charts into a personal ChatGPT account is not speed — it is future incident response.
BAAs, vendors, and the sales reality
Enterprise health buyers will ask who your subprocessors are and whether you will sign a BAA. Map vendors early: hosting, email, analytics, error tracking, AI APIs, SMS. Some excellent tools are simply not available under a BAA. Replacing them after you have production traffic is painful. Build a lightweight security packet before you need it: architecture diagram, data map, access control summary, incident response outline, and a list of certifications you have versus ones you are pursuing. Honesty beats theatre. Buyers smell fake SOC 2 claims.
Clinical safety is a product feature
If the product influences care, add human review, clear uncertainty display, and an escalation path before you chase automation metrics. Log model inputs/outputs with retention limits and access controls so you can investigate harm reports. Define what the system must never do alone. Founders like demos that “just answer.” Clinicians and compliance officers like demos that refuse unsafe asks. Build the refusal path into the MVP — it is cheaper than retrofitting governance after a scary pilot.
A sane MVP sequence
Week 0–2: scope, data map, vendor shortlist with BAA status, threat model for the top three risks. Week 3–6: thin workflow with auth, audit logs, and synthetic/de-identified data. Week 7–10: pilot with a narrow site, BAAs executed, incident contacts named, and success criteria that are clinical-operational — not vanity AI scores. Skip the fake timeline where “compliance” is a single sprint after product-market fit. In health, trust is part of product-market fit.
When to get specialists involved
Bring counsel and, when relevant, regulatory specialists if you make clinical claims, touch devices, sell into covered entities at scale, or expand across borders with different privacy regimes. Engineers can build controls; they should not invent regulatory classifications from blog posts. Your job as founder is to keep the MVP honest: smallest useful workflow, clearest data boundaries, vendors you can defend, and instrumentation that lets humans stay accountable.
Analytics, support, and the shadow IT problem
Startups leak PHI through “harmless” tools: session recordings that capture chart text, support inboxes that forward patient details to personal Gmail, product analytics that log form fields, and screenshots in Slack. Ban that casually. Configure allowlists, mask fields, and train the team that a single pasted row of patient data is an incident. Support workflows need the same discipline as product. Tickets should reference internal IDs, not raw clinical content, unless your support stack is covered and access-controlled. Founders underestimate how fast a helpful teammate becomes a compliance finding.
International and secondary use traps
If you expand beyond one country, privacy and health rules diverge. Even inside one country, using pilot data to train models, publish case studies, or sell aggregated insights may require separate consent and contracts. Keep training and product telemetry policies explicit. “We’ll anonymize later” is not a strategy if you never defined what anonymized means for your dataset. Document retention: how long encounter-adjacent data lives, who can export it, and how deletion requests propagate to backups and vendor copies. Deletion that only hides a row in the primary DB is not deletion.
